Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SYSCO Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.81 (market cap $39.89B), while SYSCO Corporation trades at $84.2 (market cap $40.09B). The key difference: Alnylam Pharmaceuticals, Inc. and SYSCO Corporation are close in size by market cap, and SYSCO Corporation pays a 2.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SYY | |
|---|---|---|
Market Cap | $39.89B | $40.09B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $91.16 |
52-Week Low | $278.09 | $69.30 |
Enterprise Value | $38.15B | $53.57B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SYY trades at $83.83, up 2.19% today, near the consensus price target of $83.67. The stock shows bullish technical signals with strong moving averages and support at $81. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed slightly. Revenue grew to $81.37B in 2025, with net income of $1.83B. The company maintains a dividend with the next payment scheduled for July 2026.
Outlook remains positive with 60% analyst buy ratings and a high target of $86. Risks include margin pressure from rising costs and competitive threats. The transformative Restaurant Depot acquisition could drive long-term growth, but investors should monitor execution and macroeconomic impacts on food distribution demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
